**Key Words:** Protein Therapeutic, LFA-1, ICAM-1, Immunosuppressant, Anti-Inflammatory, Allograft Rejection, Psoriasis and Rheumatoid Arthritis

**Application:** I-Domain as an anti-inflammatory or immunosuppressant prophylactic or therapeutic to treat atherosclerosis, allograft rejection, psoriasis, and rheumatoid arthritis. Also could serve as a target to identify highly specific antibodies.

**Inventor(s):** Timothy A. Springer, Ph.D. and Moonsoo Jin, Ph.D.

**Invention Summary:**
Inhibition of LFA-1 binding to intercellular adhesion molecule-1 (ICAM-1) is a proven and powerful point of therapeutic intervention as evidenced by Genetech’s Raptiva. Drs. Springer and Jin have developed this promising I-domain lead and additional candidates for the treatment of LFA-1 dependent ICAM-1 diseases. The I-domain is the ligand binding domain of LFA-1, and through directed mutagenesis, the engineered I-domain has a binding affinity drastically higher than wild-type. This I-domain mutant could be used as an anti-inflammatory or immunosuppressant to treat atherosclerosis, allograft rejection, psoriasis, and rheumatoid arthritis.

The I-domain has a molecular weight of 20 kDa and can be produced in a large-scale from bacteria. Therapeutics treating these disorders are Humira, Enbrel, Remicade, Kineret and Raptiva. We believe that the increase in the binding affinity to ICAM-1 and the lack of LFA-1 activation, which can be caused by approaches based on anti-LFA-1 antibody, e.g., Raptiva, will result in positive safety profiles as a result of fewer side effects.

**Publications:** *PNAS*, April 11, 2006, vol. 103, no. 15, 5758-5763

**Supporting Publications:** *Current Topics in Medicinal Chemistry* 2004, 4, 1485-1495.

PCT Application # PCT/US2006/047281, Publication # WO 2007/070488 A2

**Availability:** Exclusive worldwide license

**Contact:** Ryan Dietz
Director, Office of Technology Development
617.919.3048 dietz@idi.harvard.edu